ARTICLE
22 January 2014

The Law On Damages In Generic Drug Launches Remains Vague

W
WilmerHale

Contributor

WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
It was a stunning number, purportedly the largest patent settlement in history. During trial, defendants Teva ($1.6 billion) and Sun ($550 million) agreed to pay plaintiffs Wyeth and Nycomed a combined $2.15 billion to settle litigation stemming from their "at-risk" launches of generic versions of Wyeth and Nycomed’s Protonix product.
United States Intellectual Property

It was a stunning number, purportedly the largest patent settlement in history. During trial, defendants Teva ($1.6 billion) and Sun ($550 million) agreed to pay plaintiffs Wyeth and Nycomed a combined $2.15 billion to settle litigation stemming from their "at-risk" launches of generic versions of Wyeth and Nycomed's Protonix product.

To read the full text of this article please click here.

Originally published in the January 6, 2014 edition of the NEW YORK LAW JOURNAL © 2014 ALM Media Properties, LLC.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More